<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510663</url>
  </required_header>
  <id_info>
    <org_study_id>263-102-00005</org_study_id>
    <secondary_id>JapicCTI-183934</secondary_id>
    <nct_id>NCT03510663</nct_id>
  </id_info>
  <brief_title>Phase I Study of OPC-61815</brief_title>
  <official_title>A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effects of intravenous administration of OPC-61815 at 16 and 32 mg on&#xD;
      QT/QTc interval in healthy male subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Actual">July 5, 2018</completion_date>
  <primary_completion_date type="Actual">July 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)</measure>
    <time_frame>Baseline, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h after dosing</time_frame>
    <description>For each OPC-61815 dose, the upper limit of the confidence interval (CI) for the time-matched difference in the least squares (LS) mean for the change in QT corrected for heart rate by Fridericia's formula (QTcF) from baseline compared to the placebo data was evaluated to determine if it was lower than 10 msec at all postdose time points. Using a linear mixed effect model with baseline QTcF in each treatment period as a covariate, treatment, sequence, treatment period, time point, and interaction between treatment and time point as fixed effects, and subject as a random effect, point estimates and CIs for the time-matched difference in the LS mean for the change in QTcF from baseline compared to the placebo data were calculated.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>OPC-61815 16mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-61815 16mg will be intravenously administered once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-61815 32mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-61815 32mg will be intravenously administered once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg tablet will be administrated once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be intravenously administered once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 16mg</intervention_name>
    <description>OPC-61815 16mg will be intravenously administered once a week.</description>
    <arm_group_label>OPC-61815 16mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-61815 32mg</intervention_name>
    <description>OPC-61815 32mg will be intravenously administered once a week.</description>
    <arm_group_label>OPC-61815 32mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400mg tablet will be administrated once a week.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo will be intravenously administered once a week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) [body weight in kg / (height in m)2] of at least 18.5 kg/m2 and&#xD;
             less than 25.0 kg/m2 as a result of at the screening examination&#xD;
&#xD;
          -  Judged by the investigator or subinvestigator to be capable of providing written&#xD;
             informed consent prior to start of any trial-related procedures and capable of&#xD;
             complying with the procedures for this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a medical history of convulsive disorder, long QT syndrome (including&#xD;
             family history), syncope during swimming, or any other type of syncope or cryptogenic&#xD;
             loss of consciousness&#xD;
&#xD;
          -  Subjects with a serum electrolyte abnormality (hypokalemia, hypomagnesemia,&#xD;
             hypocalcemia, etc)&#xD;
&#xD;
          -  Subjects with a family history of sudden death&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osamu Sato</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyusyu Region</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <results_first_submitted>March 12, 2021</results_first_submitted>
  <results_first_submitted_qc>April 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2021</results_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03510663/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03510663/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1 (ABDC)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of investigational medicinal product (IMP) administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2 (DACB)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3 (BCAD)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4 (CDBA)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5 (ABCD)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6 (CADB)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P7">
          <title>Sequence 7 (BDAC)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="P8">
          <title>Sequence 8 (DCBA)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1 (ABDC)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of investigational medicinal product (IMP) administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2 (DACB)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3 (BCAD)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4 (CDBA)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B5">
          <title>Sequence 5 (ABCD)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B6">
          <title>Sequence 6 (CADB)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B7">
          <title>Sequence 7 (BDAC)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B8">
          <title>Sequence 8 (DCBA)</title>
          <description>Each subject received a single dose of each of the following 4 study treatments in Periods 1 to 4 in the assigned sequence.&#xD;
A: OPC-6181 16 mg B: OPC-61815 32 mg C: placebo D: moxifloxacin&#xD;
OPC-61815 and placebo were intravenously administered in a double-blind fashion, and a moxifloxacin 400 mg tablet was orally administered with water in an open-label fashion. A washout period of at least 6 days was set between the days of IMP administration in a treatment period and the next treatment period.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="11.4"/>
                    <measurement group_id="B2" value="27.3" spread="7.4"/>
                    <measurement group_id="B3" value="30.2" spread="7.7"/>
                    <measurement group_id="B4" value="26.5" spread="9.1"/>
                    <measurement group_id="B5" value="28.3" spread="8.4"/>
                    <measurement group_id="B6" value="30.3" spread="4.4"/>
                    <measurement group_id="B7" value="27.5" spread="4.1"/>
                    <measurement group_id="B8" value="26.2" spread="6.4"/>
                    <measurement group_id="B9" value="28.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)</title>
        <description>For each OPC-61815 dose, the upper limit of the confidence interval (CI) for the time-matched difference in the least squares (LS) mean for the change in QT corrected for heart rate by Fridericia's formula (QTcF) from baseline compared to the placebo data was evaluated to determine if it was lower than 10 msec at all postdose time points. Using a linear mixed effect model with baseline QTcF in each treatment period as a covariate, treatment, sequence, treatment period, time point, and interaction between treatment and time point as fixed effects, and subject as a random effect, point estimates and CIs for the time-matched difference in the LS mean for the change in QTcF from baseline compared to the placebo data were calculated.</description>
        <time_frame>Baseline, 1h, 1.5h, 2h, 3h, 4h, 6h, 12h, 24h after dosing</time_frame>
        <population>Central tendency analysis for OPC-61815 was performed for subjects in the Pharmacodynamic Analysis Set who appropriately completed all IMP treatments and for whom predose and postdose QT data are available for all 4 treatment periods. One subject was excluded from the central tendency analysis due to lack of QT data following OPC-61815 16 mg, OPC-61815 32 mg, and placebo administration.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-61815 16 mg</title>
            <description>OPC-61815 16 mg was intravenously administered once a week.</description>
          </group>
          <group group_id="O2">
            <title>OPC-61815 32 mg</title>
            <description>OPC-61815 32 mg was intravenously administered once a week.</description>
          </group>
          <group group_id="O3">
            <title>Moxifloxacin</title>
            <description>400 mg tablet was orally administrated once a week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo was intravenously administered once a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG)</title>
          <description>For each OPC-61815 dose, the upper limit of the confidence interval (CI) for the time-matched difference in the least squares (LS) mean for the change in QT corrected for heart rate by Fridericia's formula (QTcF) from baseline compared to the placebo data was evaluated to determine if it was lower than 10 msec at all postdose time points. Using a linear mixed effect model with baseline QTcF in each treatment period as a covariate, treatment, sequence, treatment period, time point, and interaction between treatment and time point as fixed effects, and subject as a random effect, point estimates and CIs for the time-matched difference in the LS mean for the change in QTcF from baseline compared to the placebo data were calculated.</description>
          <population>Central tendency analysis for OPC-61815 was performed for subjects in the Pharmacodynamic Analysis Set who appropriately completed all IMP treatments and for whom predose and postdose QT data are available for all 4 treatment periods. One subject was excluded from the central tendency analysis due to lack of QT data following OPC-61815 16 mg, OPC-61815 32 mg, and placebo administration.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 hour postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.1"/>
                    <measurement group_id="O2" value="0.0" spread="1.1"/>
                    <measurement group_id="O3" value="9.9" spread="1.1"/>
                    <measurement group_id="O4" value="-0.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.1"/>
                    <measurement group_id="O2" value="1.3" spread="1.1"/>
                    <measurement group_id="O3" value="9.5" spread="1.1"/>
                    <measurement group_id="O4" value="-0.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.1"/>
                    <measurement group_id="O2" value="0.4" spread="1.1"/>
                    <measurement group_id="O3" value="10.8" spread="1.1"/>
                    <measurement group_id="O4" value="-0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.1"/>
                    <measurement group_id="O2" value="-2.2" spread="1.1"/>
                    <measurement group_id="O3" value="10.9" spread="1.1"/>
                    <measurement group_id="O4" value="-0.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.1"/>
                    <measurement group_id="O2" value="-2.2" spread="1.1"/>
                    <measurement group_id="O3" value="11.1" spread="1.1"/>
                    <measurement group_id="O4" value="1.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="1.1"/>
                    <measurement group_id="O2" value="-10.8" spread="1.1"/>
                    <measurement group_id="O3" value="1.9" spread="1.1"/>
                    <measurement group_id="O4" value="-8.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="1.1"/>
                    <measurement group_id="O2" value="-9.8" spread="1.1"/>
                    <measurement group_id="O3" value="2.6" spread="1.1"/>
                    <measurement group_id="O4" value="-4.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="1.1"/>
                    <measurement group_id="O2" value="-2.8" spread="1.1"/>
                    <measurement group_id="O3" value="4.3" spread="1.1"/>
                    <measurement group_id="O4" value="-2.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-4.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>-2.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>2.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-5.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>-2.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1 hour postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>10.8</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.6</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>1.5 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>10.2</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.0</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>11.2</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.0</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>3 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>11.5</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.3</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>4 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>9.7</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>6 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>10.4</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>13.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>12 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.3</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 hours postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>7.0</param_value>
            <ci_percent>98</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>10.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events were collected from the start of IMP administration up to an average of 31 days</time_frame>
      <desc>Safety Analysis Set included subjects who received at least 1 dose of IMP and had postdose safety data.</desc>
      <group_list>
        <group group_id="E1">
          <title>OPC-61815 16 mg</title>
          <description>OPC-61815 16 mg was intravenously administered once a week.</description>
        </group>
        <group group_id="E2">
          <title>OPC-61815 32 mg</title>
          <description>OPC-61815 32 mg was intravenously administered once a week.</description>
        </group>
        <group group_id="E3">
          <title>Moxifloxacin</title>
          <description>400 mg tablet was orally administrated once a week.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo was intravenously administered once a week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Ver. 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., LTD.</organization>
      <phone>+81-3-6361-7366</phone>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

